WO2023148319 - POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE RISK
National phase entry:
Publication Number
WO/2023/148319
Publication Date
10.08.2023
International Application No.
PCT/EP2023/052660
International Filing Date
03.02.2023
Title **
[English]
POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE RISK
[French]
POLYMORPHISMES ASSOCIÉS AU RISQUE DE MALADIE D'ALZHEIMER
Applicants **
RANDOX LABORATORIES LTD
55 The Diamond Road
Crumlin Antrim BT29 4QY, GB
Inventors
SIEST, Sofia
20 Grand Rue
54470 Bernecourt, FR
PETRELIS, Alexandros
1880 route de Saint-Jeannet
Mas de Montalou
Villa 21
06700 Saint-Laurent-du-Var, FR
Priority Data
2201372.6
03.02.2022
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1000 | |
| EPO | Filing, Examination | 4591 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 9465 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
and VEGF-A-related variants and the risk of development of AD, involving novel molecular mechanisms and interactions that highlight the importance of these molecules as biomarkers for AD. A prediction model is further proposed, including nine genetic variants which appear to strongly influence the risk for AD.[French]
et des variants liés à VEGF-A et le risque de développement de MA, impliquant de nouveaux mécanismes et interactions moléculaires qui mettent en évidence l'importance de ces molécules en tant que biomarqueurs pour la MA. Un modèle de prédiction est en outre proposé, comprenant neuf variants génétiques qui semblent influencer fortement le risque de MA.